Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT03875495 Recruiting - Multiple Myeloma Clinical Trials

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

Start date: March 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be administered to up to 9 patients affected by multiple myeloma in early relapse after intensive front line treatment.

NCT ID: NCT03871829 Not yet recruiting - Multiple Myeloma Clinical Trials

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab intravenous (Dara-IV) to evaluate daratumumab retreatment.

NCT ID: NCT03870633 Not yet recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma

Start date: March 2019
Phase:
Study type: Observational

This trial studies financial difficulty in participants with chronic lymphocytic leukemia and multiple myeloma. Assessment of financial difficulty may help to better understand the financial impact of cancer and come up with ways to help participants avoid financial problems during treatment.

NCT ID: NCT03870451 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Start date: May 31, 2019
Phase: N/A
Study type: Interventional

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in hands or feet) is a common side effect of chemotherapy such as bortezomib that affects the quality of life and amount of chemotherapy that can be given to many cancer patients. Cryocompression is a treatment where a glove and a boot are worn to cool down the skin. This cooling treatment is safe and does not interfere with chemotherapy treatment. Daily cryocompression therapy may reduce neuropathy caused by bortezomib chemotherapy.

NCT ID: NCT03860038 Not yet recruiting - Clinical trials for Refractory Multiple Myeloma

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: February 28, 2019
Phase: Phase 2
Study type: Interventional

This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of treatment.

NCT ID: NCT03859427 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

ARROW2
Start date: April 23, 2019
Phase: Phase 3
Study type: Interventional

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

NCT ID: NCT03858205 Recruiting - Plasma Cell Myeloma Clinical Trials

Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

Start date: March 11, 2019
Phase: N/A
Study type: Interventional

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

NCT ID: NCT03856112 Not yet recruiting - Clinical trials for Recurrent Plasma Cell Myeloma

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Start date: June 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and side effects of venetoclax and how well it works in combination with ixazomib and dexamethasone in treating patients with t(11;14) negative multiple myeloma that has come back or does not respond to treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as venetoclax and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known how well venetoclax works with ixazomib and dexamethasone in treating patients with multiple myeloma.

NCT ID: NCT03852407 Recruiting - Multiple Myeloma Clinical Trials

Allogeneic Hematopoietic Cell Transplantation HLA-matched Donor After Flu-Mel vs Flu-Mel-ATG Conditioning

HLA
Start date: February 4, 2019
Phase: Phase 3
Study type: Interventional

The present project aims at comparing two conditioning regimens (Fludarabine-Melphalan (FM) vs Fludarabine-Melphalan-ATG (FM-ATG)). The hypothesis is that the FM-ATG regimen will be associated to better cGRFS.

NCT ID: NCT03850704 No longer available - Multiple Myeloma Clinical Trials

Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma

Start date: n/a
Phase:
Study type: Expanded Access

This is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.